<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<META NAME="ROBOTS" CONTENT="NOINDEX, NOFOLLOW, NOARCHIVE" />
<meta name="dc.language" content="eng" />
<meta name="dc.title" content="Apotex Inc. v. Sanofi-aventis (October 23, 2008)" />	
<meta name="dc.date.created" content="2008-10-24" />
<meta name="dc.date.modified" content="2008-10-24" />
<title>Apotex Inc. v. Sanofi-aventis (October 23, 2008)</title>
<style>
<!--
h1
	{text-align:center;
	page-break-after:avoid;
	font-size:15.0pt;
	font-family:"Times New Roman";
	font-weight:normal;}
h2
	{text-align:center;
	line-height:200%;
	page-break-after:avoid;
	font-size:15.0pt;
	font-family:"Times New Roman";}
h3
	{text-align:justify;
	font-size:13.0pt;
	font-family:"Times New Roman";}
h4
	{text-align:justify;
	line-height:200%;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{text-align:justify;
	tab-stops:center 216.0pt right 432.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{text-align:justify;
	tab-stops:center 216.0pt right 432.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman";}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
p.Doubleindent-quote, li.Doubleindent-quote, div.Doubleindent-quote
	{text-align:justify;
	tab-stops:108.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.DOCKETINFOFIELD, li.DOCKETINFOFIELD, div.DOCKETINFOFIELD
	{text-align:right;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.Double-indent-subquote, li.Double-indent-subquote, div.Double-indent-subquote
	{text-align:justify;
	tab-stops:144.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.headingNUMBER, li.headingNUMBER, div.headingNUMBER
	{text-align:justify;
	line-height:200%;
	tab-stops:36.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.COURTOFAPPEAL, li.COURTOFAPPEAL, div.COURTOFAPPEAL
	{text-align:center;
	font-size:15.0pt;
	font-family:"Times New Roman";}
p.StyleofCause, li.StyleofCause, div.StyleofCause
	{text-align:center;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.ParaNO, li.ParaNO, div.ParaNO
	{text-align:justify;
	line-height:200%;
	tab-stops:36.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.RespondentAppellant, li.RespondentAppellant, div.RespondentAppellant
	{text-align:right;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.Versus, li.Versus, div.Versus
	{text-align:center;
	font-size:13.0pt;
	font-family:"Times New Roman";}
p.Party, li.Party, div.Party
	{font-size:13.0pt;
	font-family:"Times New Roman";}
p.Panel, li.Panel, div.Panel
	{text-align:center;
	font-size:13.0pt;
	font-family:"Times New \(W1\)";}
ol
	{ul
	{-->
</style>
</head>
<body bgcolor="#FFFFFF" vlink=purple lang=EN-CA>
<div class=Section1>
  <table border=0 align="center" cellpadding=0 cellspacing=10>
    <tr>
      <td width=638 valign=top><p class=DOCKETINFOFIELD>CITATION:  Apotex Inc. v. Sanofi-aventis, 2008 ONCA 724</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=DOCKETINFOFIELD>DATE: 20081023</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=DOCKETINFOFIELD>DOCKET: C48363</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=COURTOFAPPEAL>COURT OF APPEAL FOR ONTARIO</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Panel>Winkler C.J.O., Sharpe J. and Juriansz JJ.A.</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p>BETWEEN:</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=StyleofCause>Apotex Inc. and Apotex Corp.</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=RespondentAppellant>Plaintiffs (Appellants)</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Versus>and</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=StyleofCause>Sanofi-aventis, Sanofi-Synthelabo Inc., Bristol-Myers
          Squibb Company and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=RespondentAppellant>Defendants (Respondents)</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party>John A. Keefe and Mark Dunn, for the appellants</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party>F. Paul Morrison, Glynnis P. Burt and Jeffrey E. Feiner, for
          the respondents Sanofi-aventis and Sanofi-Synthelabo Inc.</p>
        <p class=Party>Alan J. Lenczner, Q.C. and Marguerite Ethier, for the
          respondents Bristol-Myers Squibb Company and Bristol-Myers Squibb Sanofi
          Pharmaceuticals Holding Partnership</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party>Heard:  October 10, 2008</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party>On appeal from the Order of Justice Wailan Low of the Superior
          Court of Justice, dated January 14, 2008.</p></td>
    </tr>
    <tr>
      <td width=638 valign=top><p class=Party align=center style='text-align:center'><span style='font-size:
  15.0pt'>APPEAL BOOK ENDORSEMENT</span></p></td>
    </tr>
  </table>
  <p class=headingNUMBER style='line-height:normal'>[1]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>The motions judge gave cogent and persuasive reasons
    for concluding that there was no real and substantial connection to support
    jurisdiction and that in any event jurisdiction should be declined on the
    ground of <i>forum</i> <i>non conveniens</i>.</p>
  <p class=headingNUMBER style='line-height:normal'>[2]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>We are in substantial agreement with those reasons and
    we are satisfied that there are no grounds upon which this Court could
    interfere with the result.  </p>
  <p class=headingNUMBER style='line-height:normal'>[3]<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Appeal dismissed.  Costs on consent fixed at $15,000 for each respondent.</p>
</div>
</body>
</html>
